Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms

25Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Purpose: We hypothesized that surrogate markers of host immune response may predict survival in myeloid malignancies. Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest. Patients and Methods: Two independent cohorts of patients with primary myelofibrosis (PMF) or myelodysplastic syndromes (MDS) were studied. Kappa (κ) and lambda (λ) FLCs were measured by a quantitative nephelometric assay. Patients with monoclonal FLC were excluded. Results: Values that were above the upper limit of normal for κ or λ FLC were documented in 33% of 240 patients with PMF and 46% of 74 patients with MDS. Increased FLC was significantly associated with increased creatinine, and advanced age in PMF (P

Cite

CITATION STYLE

APA

Pardanani, A., Lasho, T. L., Finke, C. M., Rajkumar, S. V., Singh, P. P., Ketterling, R. P., … Tefferi, A. (2012). Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. Journal of Clinical Oncology, 30(10), 1087–1094. https://doi.org/10.1200/JCO.2011.39.0310

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free